Position in GUTS
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$641,200
-$1,118,800 QoQ
Shares Held
1,400,000
+75.0% QoQ
Ownership
0.882%
of shares outstanding
% of Portfolio
0.52%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CM Management, LLC holds $27,887,100 across 17 Biotechnology names. GUTS ranks #10 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RIGL |
Rigel Pharmaceuticals Inc
|
235,000 | $6,354,400 | |
| 2 | RPRX |
Royalty Pharma plc
|
125,000 | $5,996,250 | |
| 3 | CHRS |
Coherus Oncology, Inc.
|
2,100,000 | $3,549,000 | |
| 4 | ELDN |
Eledon Pharmaceuticals, Inc.
|
650,000 | $2,002,000 | |
| 5 | AVIR |
Atea Pharmaceuticals, Inc.
|
355,000 | $1,909,900 | |
| 6 | IOVA |
Iovance Biotherapeutics, Inc.
|
450,000 | $1,579,500 | |
| 7 | COYA |
Coya Therapeutics, Inc.
|
375,000 | $1,477,500 | |
| 8 | XOMA |
XOMA Royalty Corp
|
40,000 | $1,254,800 |
All Filings in GUTS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $641,200 | 1,400,000 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $1,760,000 | 800,000 | Shares | Sole | 2026-02-02 | |
| 2025-09-30 | $954,000 | 600,000 | Shares | Sole | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||